Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanosonics Limited ( (AU:NAN) ) just unveiled an update.
Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, reflecting its strong financial position and confidence in long-term growth. This initiative is part of the company’s capital management strategy, supported by its cash reserves and history of predictable cash flows, and aims to deliver long-term value to shareholders while maintaining a strong balance sheet and investing in future growth opportunities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is a global leader in infection prevention, known for its trophon® device sales and recurring revenue from consumables and services. The company focuses on innovation in infection prevention, with products like trophon3, trophon2 Plus, and the CORIS system, which has received FDA De Novo approval.
Average Trading Volume: 737,564
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.37B
See more data about NAN stock on TipRanks’ Stock Analysis page.